Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053423 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
A Phase 4 study of Chronic Obstructive Pulmonary Disease, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT07053423 is a Phase 4 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Sanofi. The registered enrollment target is 218 participants, below the 1,751-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT07053423, a Phase 4 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive). Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (20)
Other
- Investigational Site Number : 0320002 - Buenos Aires
- Investigational Site Number : 0320003 - Buenos Aires
- Incor - Instituto do Coracao- Site Number : 0760001 - São Paulo
- Investigational Site Number : 1560001 - Guangzhou
- Investigational Site Number : 2080003 - Aalborg
- Investigational Site Number : 2080002 - Vejle
- Investigational Site Number : 2500008 - La Tronche
- Investigational Site Number : 2500001 - Lille
- Investigational Site Number : 2500005 - Lyon
- Investigational Site Number : 2500006 - Marseille
- Investigational Site Number : 2500002 - Montpellier
- Investigational Site Number : 2500003 - Pessac
- Investigational Site Number : 2500004 - Reims
Alabama
- University of Alabama at Birmingham - School of Medicine- Site Number : 8400003 - Birmingham
Florida
- Finlay Medical Research- Site Number : 8400010 - Miami
North Carolina
- American Health Research - Charlotte- Site Number : 8400013 - Charlotte
Pennsylvania
- Clinical Research Associates of Central PA- Site Number : 8400002 - DuBois
Texas
- REX Clinical Trials - Beaumont- Site Number : 8400011 - Beaumont
Tucumán Province
- Investigational Site Number : 0320001 - San Miguel de Tucumán
Rio Grande do Sul
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760002 - Porto Alegre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2029-02-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053423
The ClinicalTrials.gov registry entry for NCT07053423 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,751-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (88% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07053423 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT07053423 about?
NCT07053423 is a clinical study titled "A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.". LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its a...
What is the current status of trial NCT07053423?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 218 participants. The study started on 2025-09-22. Estimated completion is 2029-02-15.
What conditions does trial NCT07053423 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07053423?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT07053423?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053423 being conducted?
This trial has 20 study locations across Alabama, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
-
Nebulized Hypertonic Saline for Inpatient Use in COPD
COMPLETED · Phase 4
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.